Erlonat 150mg Tablet (Erlotinib 150mg) is a selective EGFR-TKI for EGFR-mutant NSCLC and pancreatic cancer. Composition: Each tablet contains 150mg Erlotinib HCl. Indications: First-line NSCLC treatment with EGFR mutations, maintenance therapy post-chemotherapy, pancreatic cancer with gemcitabine. Contraindications: Severe hepatic/renal impairment, severe lung disease, hypersensitivity. Relative caution with baseline GI disease, cardiac dysfunction. Drug Interactions: CYP3A4 modulation, antacids requiring separation. Dosage: 150mg daily on empty stomach, adjustable to 100-200mg based on tolerability. Storage: 15-30°C. Side Effects: Diarrhea (50-70%), rash (75-90%), stomatitis, anorexia, fatigue. Serious: interstitial lung disease, hepatotoxicity, GI perforation. Precautions: Monthly LFTs; baseline and periodic chest imaging; diarrhea prophylaxis essential; skin care protocol. Pregnancy: Category D, absolutely contraindicated. Substitutes: Gefitinib, Afatinib, Osimertinib for resistant disease. FAQs: Response 4-8 weeks; diarrhea management critical; cost varies; treatment until progression. Expected Timeline: Week 4 assessment, Week 8 imaging, Month 3 response confirmation. Book Oncology Consultation: EGFR testing, toxicity management, surveillance protocols. Schedule Tests: Monthly LFTs; baseline/monthly chest X-ray; baseline ECG; monthly clinical review.